Index test:plasma ctDNA

2 trials

Sponsors

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Affiliated Hospital of Guangdong Medical University

Conditions

Ovarian cancerstage II/III non-small cell lung cancer

Early Phase 1

Postoperative MRD monitoring of stage II/III NSCLC by using high-sensitivity ctDNA detection method (ATGseq)

RecruitingChiCTR1900024656

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Collegestage II/III non-small cell lung cancer

Start: 2019-07-19Updated: 2019-07-22

Unknown Phase

Dynamic monitoring of residual tumor lesions based on plasma circulating tumor DNA (ctDNA) for prognosis and treatment evaluation of patients with ovarian cancer undergoing surgical resection

RecruitingChiCTR2300072927

Affiliated Hospital of Guangdong Medical UniversityOvarian cancer

Start: 2022-11-08Updated: 2023-07-02

Related Papers

Circulating tumor DNA as markers of dynamic recurrence risk and adjuvant chemotherapy benefit in resected non-small cell lung cancer.

Journal of Clinical Oncology2021-05-202 citations